| Trial registration number
|
NCT04871646 |
Full text link
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04871646
|
First author
Last imported at : Aug. 3, 2021, 1:30 p.m.
Source : ClinicalTrials.gov
|
Dasom Kim
|
Contact
Last imported at : Aug. 3, 2021, 1:30 p.m.
Source : ClinicalTrials.gov
|
dasom@ckdpharm.com
|
Registration date
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
2021-05-04
|
Recruitment status
Last imported at : July 6, 2023, midnight
Source : ClinicalTrials.gov
|
Unknown
|
Study design
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
patients aged ≥ 18 years
patients diagnosed with covid-19 infection and pneumonia
patients who have voluntarily decided to participate in the study and signed the informed consent form if a patient cannot provide consent on his or her own, informed consent by a legally authorized representative may be obtained.
|
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov
|
patients with history of hypersensitivity to the study drug
female patients, either who are or may be pregnant or who are breastfeeding, or female patients of child-bearing potential who are unable to use adequate contraception during the study
patients who are deemed to ineligible to participate in the study for other reasons by the investigator
|
Number of arms
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Chong Kun Dang Pharmaceutical
|
Inclusion age min
Last imported at : Aug. 3, 2021, 1:30 p.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Korea;Republic of
|
Type of patients
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Severe/critical disease at enrollment
|
Severity scale
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
7: Severe/critical disease at enrollment
|
Total sample size
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
586
|
primary outcome
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Time to recovery
|
Notes
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
Phase 3
|
Arms
Last imported at : May 5, 2021, 11:25 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 291, "treatment_name": "Ckd-314", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
|